Navigation Links
Reportlinker Adds Breast Cancer Drug Futures
Date:10/19/2010

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Breast Cancer Drug Futures

http://www.reportlinker.com/p0315762/Breast-Cancer-Drug-Futures.html

AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Breast Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.

24/7 web access

Quarterly updated pdf reports

Single cost-effective price

All updates including any new drugs added during your license period

Related news

Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

Globally, breast cancer is the second most common cancer after lung cancer....

....and the most common cancer for women. It is the second most common cause of death from cancer in women after lung cancer.

The breast cancer market is a steadily growing market due to effective treatments which have decreased mortality and resulted in a longer duration of therapy. The five-year survival rates for women with breast cancer have increased from under 70% 50 years ago to around 90% now.

Approximately 47% of breast cancer sales were derived from the US, with 41% Europe and 12% in Japan. Over the next six years Espicom forecasts that novel therapies including targeted monoclonal antibodies and small-molecule inhibitors, will increasingly be used in combination with chemotherapy and hormonal therapy.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Breast Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...

Track the drug's progress and stay in-touch with developments

Understand the drug's novelty and mode of action

Evaluate the strength of the company developing/producing the drug

Review opportunities and challenges with Espicom's unique 5-point competitive assessment

Know the launch timeframe for new products or indications

Be aware of promising mid-stage development candidates

Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates

Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…

Novelty/rationale for mechanism of action

Current status

Proof of concept/clinical data

Development risks

Company expertise

Competition within the market-place

Sales forecast (for key late-stage and launched products)

Competitor ratio analysis score

Clinical trial results

OVER 65 CURRENT PROJECTS COVERED:

Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved

Anastrozole

Bevacizumab

BIIB021

Capecitabine

Docetaxel

Doxorubicin

Fulvestrant

Gemcitabine

Goserelin

Ixabepilone

Lapatinib

Letrozole

Paclitaxel

Pazopanib

Saracatinib

Tamoxifen

Tegafur+gimeracil+oteracil

Tegafur+uracil

Phase III

Erbulin

Everolimus

Pertuzumab

Ramucirumab

Trabectedin

Vadimezan

Phase II/III

Pazopanib

Phase II

AE37

Axitinib

Bavituximab

Cixutumumab

E75 GM-CSF adjuvant vaccine

Figitumumab

Gimatecan

Linifanib

Motesanib diphosphate

NOV-002

Olaparib

Pemetrexed disodium

Retaspimycin

Sorafenib

SU14813

TSU-68

YM155

Phase I/II

AUY922

BIIB021

IMP321

MVA-BN-HER2

Tivozanib

Phase I

Adecatumumab

Brivanib

PTC299

Withdrawn

Saracatinib

Sagopilone

Sunitinib malate

Development Discontinued

ABT-751

CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years' of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom's Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom's tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom's leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

Table of Contents

OVERVIEW .... 1

ADECATUMUMAB .... 4

Mode of Action .. 4

Current Status ... 4

Proof of Concept/Clinical Data ... 4

Development Risks . 5

Company Expertise . 5

Competition within the Market-place 5

Clinical Trial Results .... 5

GDC-0941 8

Mode of Action .. 8

Current Status ... 8

Company Expertise . 8

BRIVANIB 9

Mode of Action .. 9

Current Status ... 9

Proof of Concept/Clinical Data ... 9

Development Risks . 9

Company Expertise 10

Competition within the Market-place ....10

Competitor Ratio Analysis ....11

Forecast ...11

PTC299 . 13

Mode of Action 13

Current Status .13

Proof of Concept/Clinical Data .13

Development Risks 14

Company Expertise 14

AUY922 . 15

Mode of Action 15

Current Status .15

Proof of Concept/Clinical Data .16

Development Risks 16

Company Expertise 16

Competition within the Market-place ....16

Competitor Ratio Analysis ....16

BIIB021 . 18

Mode of Action 18

Current Status .18

Proof of Concept/Clinical Data .18

Development Risks 18

Company Expertise 18

Competition within the Market-place ....18

Competitor Ratio Analysis ....19

DASATINIB .. 20

Mode of Action 20

Current Status .20

Proof of Concept/Clinical Data .20

Development Risks 21

Company Expertise 21

Competition within the Market-place ....22

Competitor Ratio Analysis ....22

Forecast ...22

Clinical Trial Results ....23

Chronic Myelogenous Leukaemia .... 23

IMP321 .. 26

Mode of Action 26

Current Status .26

Proof of Concept/Clinical Data .26

Company Expertise 27

Competition within the Market-place ....27

Competitor Ratio Analysis ....27

ISPINESIB ... 28

Mode of Action 28

Current Status .28

Clinical Trial Results ..28

MVA-BN-HER2 .. 29

Mode of Action 29

Current Status .29

Proof of Concept/Clinical Data .29

Development Risks 29

Company Expertise 29

Competition within the Market-place ....30

Competitor Ratio Analysis ....30

TIVOZANIB .. 31

Mode of Action 31

Current Status .31

Proof of Concept/Clinical Data .31

Development Risks 32

Company Expertise 32

Competition within the Market-place ....33

Competitor Ratio Analysis ....33

Forecast ...33

AE37 ..... 35

Mode of Action 35

Current Status .35

Proof of Concept/Clinical Data .35

Development Risks 36

Company Expertise 36

Competition within the Market-place ....36

Competitor Ratio Analysis ....36

AXITINIB 37

Mode of Action 37

Current Status .37

Proof of Concept/Clinical Data .37

Development Risks 38

Company Expertise 38

Competition within the Market-place ....39

Competitor Ratio Analysis ....40

Forecast ...40

Clinical Trial Results ..41

BAVITUXIMAB .. 43

Mode of Action 43

Current Status .43

Proof of Concept/Clinical Data .43

Development Risks 44

Company Expertise 44

Competition within the Market-place ....44

Competitor Ratio Analysis ....45

BIBW 2992 ... 46

Mode of Action 46

Current Status .46

Proof of Concept/Clinical Data .47

Development Risks 47

Company Expertise 47

Competition within the Market-place ....48

Competitor Ratio Analysis ....48

Forecast ...48

Clinical Trial Results ..49

BOSUTINIB . 51

Mode of Action 51

Current Status .51

Clinical Trial Results ....51

CIXUTUMUMAB 52

Mode of Action 52

Current Status .52

Proof of Concept/Clinical Data .52

Development Risks 53

Company Expertise 53

Competition within the Market-place ....53

Competitor Ratio Analysis ....53

E75 GM-CSF ADJUVANT VACCINE ..... 54

Mode of Action 54

Current Status .54

Proof of Concept/Clinical Data .54

Development Risks 54

Company Expertise 55

Competition Within the Market-place ...55

Competitor Ratio Analysis ....56

Forecast ...56

FIGITUMUMAB .. 57

Mode of Action 57

Current Status .57

Proof of Concept ...57

Development Risks 58

Company Expertise 58

Competition within the Market-place ....58

Competitor Ratio Analysis ....59

GIMATECAN ..... 61

Mode of Action 61

Proof of Concept/Clinical Data .61

LINIFANIB ... 62

Mode of Action 62

Current Status .62

Proof of Concept/Clinical Data .62

Development Risks 63

Company Expertise 63

Competition within the Market-place ....63

Competitor Ratio Analysis ....64

MOTESANIB DIPHOSPHATE ... 65

Mode of Action 65

Current Status .65

Proof of Concept/Clinical Data .65

Development Risks 65

Company Expertise 65

Competition within the Market-place ....66

Competitor Ratio Analysis ....67

Forecast ...67

NOV-002 70

Mode of Action 70

Current Status .70

Proof of Concept ...70

Development Risks 71

Company Expertise 71

Competition within the Market-place ....71

Competitor Ratio Analysis ....72

Forecast ...72

OLAPARIB .. 73

Mode of Action 73

Current Status .73

Proof of Concept/Clinical Data .73

Development Risks 74

Company Expertise 74

Competition within the Market-place ....75

Competitor Ratio Analysis ....75

RETASPIMYCIN 76

Mode of Action 76

Current Status .76

Proof of Concept/Clinical Data .76

Development Risks 76

Company Expertise 77

Competition within the Market-place ....77

Competitor Ratio Analysis ....78

RETASPIMYCIN 79

Mode of Action 79

Current Status .79

Proof of Concept/Clinical Data .79

Development Risks 79

Company Expertise 80

Competition within the Market-place ....80

Competitor Ratio Analysis ....81

SORAFENIB 82

Mode of Action 82

Current Status .82

Proof of Concept/Clinical Data .84

Development Risks 84

Company Expertise 85

Competition within the Market-place ....85

Data Exclusivity .....86

Patent Expiry ...86

Competitor Ratio Analysis ....87

Forecast ...87

SU14813 90

Mode of Action 90

Current Status .90

TAS-108 . 91

Mode of Action 91

Current Status .91

TSU-68 .. 92

Mode of Action 92

Current Status .92

Proof of Concept/Clinical Data .92

Development Risks 92

Company Expertise 92

Competition within the Market-place ....92

Competitor Ratio Analysis ....93

VANDETANIB .... 94

Mode of Action 94

Current Status .94

Proof of Concept/Clinical Data .94

Development Risks 94

Company Expertise 94

Competition Within the Market-place ...95

Competitor Ratio Analysis ....95

Forecast ...95

Clinical Trial Results ..96

YM155 ... 97

Current Status .97

Proof of Concept/Clinical Data .97

CANFOSFAMIDE .... 98

Mode of Action 98

Current Status .98

Proof of Concept/Clinical Data .98

Development Risks 99

Company Expertise 99

Competition within the Market-place ....99

Competitor Ratio Analysis ..100

PAZOPANIB .... 101

Mode of Action ....101

Current Status .....101

Proof of Concept/Clinical Data .....101

Development Risks ....102

Company Expertise ....102

Competition within the Market-place ..103

Data Exclusivity ...103

Patent Expiry .103

Competitor Ratio Analysis ..104

Forecast .104

Clinical Trial Results 106

BSI-201 107

Mode of Action ....107

Current Status .....107

Proof of Concept/Clinical Data .....108

Development Risks ....108

Company Expertise ....108

Competition within the Market-place ..108

Competitor Ratio Analysis ..109

Clinical Trial Results 109

ERBULIN ... 110

Clinical Trial Results 110

EVEROLIMUS . 111

Mode of Action ....111

Current Status .....112

Proof of Concept/Clinical Data .....113

Development Risks ....115

Company Expertise ....115

Competition within the Market-place ..116

Competitor Ratio Analysis ..117

Forecast .117

NERATINIB 122

Mode of Action ....122

Current Status .....122

Proof of Concept/Clinical Data .....122

Development Risks ....122

Company Expertise ....122

Clinical Trial Results 123

PERTUZUMAB 124

Mode of Action ....124

Current Status .....124

Proof of Concept/Clinical Data .....124

Development Risks ....125

Company Expertise ....125

Competition within the Market-place ..125

Competitor Ratio Analysis ..126

Forecast .126

Clinical Trial Results 127

RAMUCIRUMAB .... 129

Mode of Action ....129

Current Status .....129

Proof of Concept/Clinical Data .....129

Development Risks ....129

Company Expertise ....129

Competition within the Market-place ..130

Competitor Ratio Analysis ..130

Forecast .130

TRABECTIDIN . 132

Mode of Action ....132

Current Status .....132

Further Development .132

VADIMEZAN .... 135

Mode of Action ....135

Current Status .....135

Proof of Concept/Clinical Data .....136

Development Risks ....136

Company Expertise ....136

Competition Within the Market-place .137

Competitor Ratio Analysis ..137

Forecast .137

Clinical Trial Results 138

ANASTROZOLE .... 140

Mode of Action ....140

Current Status .....140

Proof of Concept/Clinical Data .....141

Development Risks ....142

Company Expertise ....142

Competition Within the Market-place .143

Data Exclusivity ...143

Patent Expiry .143

Generic Competition 144

Competitor Ratio Analysis ..144

Forecast .144

Clinical Trial Results 145

BEVACIZUMAB ..... 148

Mode of Action ....148

Current Status .....148

Proof of Concept/Clinical Data .....151

Development Risks ....154

Company Expertise ....155

Competition within the Market-place ..156

Competitor Ratio Analysis ..157

Forecast .158

CAPECITABINE .... 165

Mode of Action ....165

Current Status .....165

Proof of Concept/Clinical Data .....167

Development Risks ....169

Company Expertise ....169

Competition within the Market-place ..169

Patent Expiry .170

Competitor Ratio Analysis ..170

Forecast .170

Clinical Trial Results 173

DOCETAXEL ... 176

Mode of Action ....176

Current Status .....176

Proof of Concept .179

Development Risks ....184

Company Expertise ....185

Competition within the Market-place ..185

Competitor Ratio Analysis ..186

Forecast .187

DOXIFLURIDINE ... 190

Mode of Action ....190

Current Status .....190

DOXORUBICIN 191

Clinical Trial Results 191

EXEMESTANE 192

Mode of Action ....192

Current Status .....192

Proof of Concept/Clinical Data .....192

Development Risks ....193

Company Expertise ....193

Competition within the Market-place ..193

Data Exclusivity ...193

Patent Expiry .194

Competitor Ratio Analysis ..194

Forecast .194

FULVESTRANT ..... 196

Mode of Action ....196

Sales .196

Current Status .....196

Proof of concept/clinical data .196

Development Risks ....197

Company Expertise ....198

Competition within the Market-place ..198

Competitor Ratio Analysis ..198

Forecast .199

GEMCITABINE 200

Current Status .....200

Proof of Concept/Clinical Data .....201

Development Risks ....202

Company Expertise ....202

Competition within the Market-place ..203

Patent Expiry .203

Generic Competition 203

Competitor Ratio Analysis ..205

Forecast .205

Clinical Trial Results 206

Metastatic Breast Cancer .. 206

Pancreatic Cancer. 207

GOSERELIN .... 209

Mode of Action ....209

Sales .209

Current Status .....209

Proof of Concept .211

Development Risks ....211

Company Expertise ....212

Competition Within the Market-place .212

Competitor Ratio Analysis ..213

Forecast .213

IXABEPILONE . 215

Mode of Action ....215

Current Status .....215

Proof of Concept/Clinical Data .....215

Development Risks ....216

Company Expertise ....216

Competition within the Market-place ..217

Competitor Ratio Analysis ..217

Forecast .217

Clinical Trial Results 218

LAPATINIB 220

Mode of Action ....220

Current Status .....220

Proof of Concept/Clinical Data .....221

Development Risks ....222

Company Expertise ....223

Competition within the Market-place ..223

Data Exclusivity ...223

Patent Expiry .224

Competitor Ratio Analysis ..224

Forecast .224

Clinical Trial Results 226

LETROZOLE ... 227

Mode of Action ....227

Current Status .....227

Proof of Concept .228

Development Risks ....228

Company Expertise ....228

Competition within the Market-place ..229

Patent Expiry .229

Generic Competition 229

Competitor Ratio Analysis ..229

Forecast .229

Clinical Trial Results 230

PACLITAXEL ALBUMIN-BOUND PARTICLES .... 232

Mode of Action ....232

Current Status .....232

Proof of Concept .233

Development Risks ....233

Company Expertise ....234

Competition Within the Market-place .234

Data Exclusivity .... 235

Patent Expiry .. 235

Generic Competition 235

Competitor Ratio Analysis ..235

Forecast .236

Clinical Trial Results 236

PACLITAXEL ... 238

RALOXIFENE .. 239

Mode of Action ....239

Current Status .....239

Proof of Concept .240

Development Risks ....241

Company Expertise ....241

Competition within the Market-place ..241

Data Exclusivity ...242

Patent Expiry .242

Generic Competition ..242

Competitor Ratio Analysis ..243

Forecast .243

Clinical Trial Results 244

TAMOXIFEN .... 246

Mode of Action ....246

Current Status .....246

Proof of Concept/Clinical Data .....246

Development Risks ....247

Company Expertise ....247

Competition within the Market-place ..247

Data Exclusivity ...247

Generic Competition 248

Competitor Ratio Analysis ..248

Forecast .248

TOREMIFENE .. 250

Mode of Action ....250

Current Status .....250

Proof of Concept/Clinical Data .....250

Development Risks ....251

Company Expertise ....251

Competition within the Market-place ..252

Competitor Ratio Analysis ..252

TRASTUZUMAB .... 253

Mode of Action ....253

Current Status .....253

Proof of Concept/Clinical Data .....255

Development Risks ....257

Company Expertise ....257

Competition within the Market-place ..258

Patent Expiry .259

Competitor Ratio Analysis ..259

Forecast .259

Clinical Trial Results 260

ABT-751 .... 263

Mode of Action ....263

Current Status .....263

ARZOXIFENE .. 264

Mode of Action ....264

Current Status .....264

Proof of Concept/Clinical Data .....264

ENZASTAURIN 265

Mode of Action ....265

Current Status .....265

Proof of Concept/Clinical Data .....265

Development Risks ....265

Company Expertise ....266

Competition within the Market-place ..266

Competitor Ratio Analysis ..266

Forecast .267

Clinical Trial Results 267

SAGOPILONE . 268

Mode of Action ....268

Current Status .....268

Proof of Concept/Clinical Data .....268

Company Expertise ....268

Competition within the Market-place ..269

Competitor Ratio Analysis ..269

PD-325901 . 270

Mode of Action ....270

Current Status .....270

Proof of Concept/Clinical Data .....270

SARACATINIB 271

Mode of Action ....271

Current Status .....271

SUNITINIB MALATE ... 272

Mode of Action ....272

Current Status .....272

Proof of Concept/Clinical Data .....273

Development Risks ....274

Company Expertise ....275

Competition within the Market-place ..275

Data Exclusivity ...276

Patent Expiry .276

Generic Competition 276

Competitor Ratio Analysis ..277

Forecast .277

Clinical Trial Results 280

TANESPIMYCIN .... 282

Mode of Action ....282

Current Status .....282

Proof of Concept/Clinical Data .....282

Development Risks ....282

Company Expertise ....283

Competition within the Market-place ..283

Competitor Ratio Analysis ..283

METHODOLOGY ... 284

To order this report:

Biotechnology Industry: Breast Cancer Drug Futures

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Franz Inc. , ... Database technology has been recognized As “ Best in Semantic Web Technology - ... “At Corporate America, it’s our priority to showcase prominent professionals who are excelling ...
(Date:2/3/2016)... Pa. , Feb. 3, 2016  Discovery ... company focused on developing aerosolized KL4 surfactant therapies ... of Directors has approved an inducement award as ... Fraser , its newly appointed President and Chief ... Board,s Compensation Committee on February 1, 2016 and ...
(Date:2/3/2016)... N.J. , Feb. 3, 2016 ... totaling more than $1 million for researchers in ... working on health-related research that demonstrates exciting potential. ... round of funding for the New Jersey Health Foundation ... faculty members at these educational institutions— Princeton University, ...
(Date:2/3/2016)... ... 03, 2016 , ... Resilinc released online today ... nearly 750 unique supply chain notifications and alerts generated by its EventWatch ... risk management practitioners subscribe to the EventWatch service to receive early warnings and ...
Breaking Biology Technology:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):